论文部分内容阅读
ＡｓｔｒａＺｅｎｅｃａ公司说它将继续关注ｇｅｆｉｔｉｎｉｂ(Ｉｒｅｓ ｓａ)复合化疗对非小细胞肺癌的疗效 ,尽管ｇｅｆｉｔｉｎｉｂ复合治疗非小细胞肺癌临床试验 (ＩＮＴＡＣＴ)已经失败 ,试验报告已在 2 0 0 2年 10月的尼斯会议上完全公开。会上Ｇｉａｃｃｏｎｅ医生报告
AstraZeneca said it will continue to focus on the efficacy of gefitinib (Ires sa) combination chemotherapy in non-small cell lung cancer, although the trial of gefitinib in combination with non-small cell lung cancer (INTACT) has failed and the test report was published in October 2002 Nice meeting completely open. Dr. Giaccone reports at the meeting